Invirsa key facts
as of Oct 2026- Developer of a therapeutic platform designed to treat infectious and inflammatory eye diseases through activation of innate cellular defense and repair pathways.
- Invirsa is valued at approximately $38.0M as of Oct 2026 (last reported valuation).
- It has raised $14.3M across 3 recorded rounds; the latest was Seed Round ($2.9M) in Jul 2025.
- Notable investors include Endless Frontier Labs, Jumpstart Ventures, JobsOhio Ventures, Rev1 Ventures, CincyTech — 8 tracked in total.
- Invirsa has filed 5 Form Ds with the SEC since 2020, most recently Aug 2025 ($2.9M sold to 14 investors).
- Status: Privately Held (backing).
Invirsa's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·Watch Invirsa: the Monday email on marks, rounds and moves
Invirsa funding rounds
3 roundsInvirsa valuation
Invirsa's last reported valuation was $38 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Invirsa raised?
Invirsa has raised $14.3 million across 3 recorded rounds since 2022. The largest was a $1 million seed round in Nov 2023; the most recent was a $2.9 million seed round in Jul 2025.
Invirsa has filed 5 Form Ds with the SEC since 2020, most recently in Aug 2025 ($2.9 million sold to 14 investors).
Invirsa investors
8 investors are on record for Invirsa, including Endless Frontier Labs, Jumpstart Ventures, JobsOhio Ventures and Rev1 Ventures. The seed round in Jul 2025 drew 14 investors.
About Invirsa
Developer of a therapeutic platform designed to treat infectious and inflammatory eye diseases through activation of innate cellular defense and repair pathways. The company offers a novel approach demonstrating clinical efficacy in diabetic dry eye and infectious conjunctivitis, enabling patients with ocular surface disorders to experience improved healing and reduced disease burden.
- Sector
- Healthcare
- HQ
- Columbus, OH, United States
- Founded
- 2014
- Employees
- 8
- Website
- invirsa.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.